Commentary|Videos|November 16, 2026

Menopause Benefit Design Should Prioritize Access, Total Cost of Care

Fact checked by: Laura Joszt, MA

Crescent Moore, PharmD, PhD, explained how health plans can evaluate menopause therapies, audit coverage, and measure outcomes beyond spending.

Health plans should evaluate new menopause therapies with the same clinical and safety lens they apply to any other drug, while ensuring utilization management supports access rather than restricts it, according to Crescent Moore, PharmD, PhD, senior vice president of clinical strategy and product at LucyRx.

In part 2 of an interview with The American Journal of Managed Care® at the Academy of Managed Care Pharmacy Nexus 2026 meeting, Moore, a panelist during the “Integrating Perimenopause and Menopause Care into the Pharmacy Benefit: A Managed Care Framework for Improving Women's Health Outcomes” session, discussed how plans can assess therapies in this space, where to begin with benefit design, and which outcomes matter most.

Moore began by noting that plans should consider whether trial outcomes were clinically meaningful and evaluate the safety profile of each agent. As more therapies come to market, plans will be able to compare them across the class to identify those with the best outcomes and most favorable adverse effect profiles. When plans implement utilization management for a covered therapy, their criteria should focus on getting the right patient the right drug without placing unnecessary burdens on patients or prescribers, she said.

Next, Moore described a “progress over perfection” approach to benefit design. Plans do not need to change everything at once, she said, and should start by auditing their current coverage. Since not every woman can use the same formulations, the audit should assess whether multiple formulations are available, whether both hormonal and nonhormonal options are covered, and what utilization management requirements are in place.

Building on this, she outlined how her team measures outcomes. Nurses track patient engagement and use the validated Menopause Rating Scale to monitor psychological, somatic, and other symptoms over time. The assessment also captures perceived presenteeism and absenteeism, because many women keep working through their symptoms; Moore cited research estimating that menopause has a $1.8 billion impact on the workforce.1 Her team also tracks whether patients stay on therapy when it is clinically appropriate.

Lastly, Moore said plans should look at menopause care in terms of total cost of care rather than pharmacy spending alone. Pharmacy costs may stay flat or rise slightly once women are on appropriate therapy, but medical costs may fall. Cardiovascular risk rises significantly during perimenopause and menopause, so appropriate treatment could help prevent emergency department visits and inpatient stays, she noted.

“We have that opportunity to reduce that risk for [emergency department] visits or inpatient visits, and…in the end, it helps our health care system, and it helps the patient as well,” Moore concluded.

Reference

  1. Faubion SS, Enders F, Hedges MS, et al. Impact of menopause symptoms on women in the workplace. Mayo Clin Proc. 2023;98(6):833-845. doi:10.1016/j.mayocp.2023.02.025

Related to this article